Saturday, October 08, 2005

Oral ZYVOX® shows cost savings for outpatient treatment of skin, other infections vs. vancomycin

SAN FRANCISCO, October 7, 2005 – Oral ZYVOX® (linezolid) was associated with significant savings to the health care system – an average of $4,630 per patient – compared to vancomycin when used in an outpatient setting for people with certain infections, according to data to be presented today at the Infectious Diseases Society of America (IDSA) annual meeting. In the study, patients taking oral ZYVOX had fewer physician office visits, emergency room visits, hospitalizations, lab tests and other health care services, as well as lower total costs, compared to patients taking vancomycin......Read more from Eureka Alert

posted by Clay @ 10/08/2005 07:16:00 AM   0 comments


Post a Comment

<< Home

Disclaimer: This blog is for entertainment purposes. If you are a doctor, practice at your own risk.